Elicio Therapeutics: First Patient Dosed in ELI-002’s Trial in KRAS-Driven Cancers – CBI
Homepage /  Press Release /  Elicio Therapeutics: First Patient Dosed in ELI-002’s Trial in KRAS-Driven Cancers

Press Release

Elicio Therapeutics: First Patient Dosed in ELI-002’s Trial in KRAS-Driven Cancers